Search

Your search keyword '"Trociukas, Igoris"' showing total 20 results
Start Over Author "Trociukas, Igoris"
20 results on '"Trociukas, Igoris"'

10. Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting

Author

Žucenka, Andrius, primary, Kevličius, Lukas, additional, Davainis, Linas, additional, Davainienė, Birutė, additional, Maneikis, Kazimieras, additional, Pileckytė, Regina, additional, Vasilevska, Dominika, additional, Trociukas, Igoris, additional, Vaitekėnaitė, Vilmantė, additional, and Griškevičius, Laimonas, additional

Published
2022
Full Text
View/download PDF

11. AML-672 Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)

Author

Kevlčius, Lukas, Smalinskaitė, Tautvilė, Trociukas, Igoris, Pileckytė, Regina, Čekauskienė, Rita, Davainis, Linas, Daukėlaitė, Guoda, Vaitekėnaitė, Vilmantė, Strumskytė, Justė, Jaraminė, Vaida, Slobinas, Artūras, Jucaitienė, Renata, Šlepikienė, Inga, Bukauskas, Adomas, Stoškus, Mindaugas, Batiuškaitė, Raminta, Norvilas, Rimvydas, Velčeckienė, Vilma, Valentinė, Eglė Gineikienė, Dirsė, Vaidas, Griškevičius, Laimonas, and Žučenka, Andrius

Published
2024
Full Text
View/download PDF

12. Venetoclax-Based Preconditioning Followed by Immediate Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)

Author

Kevličius, Lukas, Smalinskaitė, Tautvilė, Trociukas, Igoris, Pileckytė, Regina, Čekauskienė, Rita, Davainis, Linas, Daukėlaitė, Guoda, Vaitekėnaitė, Vilmantė, Strumskytė, Justė, Jaraminė, Vaida, Slobinas, Artūras, Jucaitienė, Renata, Šlepikienė, Inga, Bukauskas, Adomas, Stoškus, Mindaugas, Batiuškaitė, Raminta, Norvilas, Rimvydas, Velčeckienė, Vilma, Gineikienė Valentinė, Eglė, Dirsė, Vaidas, Griškevičius, Laimonas, and Žučenka, Andrius

Published
2024
Full Text
View/download PDF

15. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies

Author

Zucenka, Andrius, primary, Pileckyte, Regina, additional, Trociukas, Igoris, additional, Peceliunas, Valdas, additional, Vaitekenaite, Vilmante, additional, Maneikis, Kazimieras, additional, Davainis, Linas, additional, Zvirblis, Tadas, additional, Stoskus, Mindaugas, additional, Gineikiene, Egle, additional, Norvilas, Rimvydas, additional, Dirse, Vaidas, additional, Surauciute, Agne, additional, Zucenkiene, Emile, additional, and Griskevicius, Laimonas, additional

Published
2020
Full Text
View/download PDF

16. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J., Mullane, Kathleen M., Cornely, Oliver A., Boeckh, Michael J., Brown, Janice Wes, Pergam, Steven A., Trociukas, Igoris, Zak, Pavel, Craig, Michael D., Papanicolaou, Genovefa A., Velez, Juan D., Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A., Stek, Jon E., Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S. F., Kaplan, Susan S., Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W., Arvin, Ann, Winston, Drew J., Mullane, Kathleen M., Cornely, Oliver A., Boeckh, Michael J., Brown, Janice Wes, Pergam, Steven A., Trociukas, Igoris, Zak, Pavel, Craig, Michael D., Papanicolaou, Genovefa A., Velez, Juan D., Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A., Stek, Jon E., Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S. F., Kaplan, Susan S., Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W., and Arvin, Ann

Abstract

Background Recipients of autologous haemopoietic stem-cell transplants (auto-HSCT) have an increased risk of herpes zoster and herpes zoster-related complications. The aim of this study was to establish the efficacy and safety of an inactivated varicella zoster vaccine for the prevention of herpes zoster after auto-HSCT. Methods In this randomised, double-blind, placebo-controlled phase 3 trial, participants were recruited from 135 medical centres (ie, stem-cell transplant centres and hospitals) in North America, South America, Europe, and Asia. Patients were eligible if they were aged 18 years or older, scheduled to receive an auto-HSCT within 60 days of enrolment, and had a history of varicella infection or were seropositive for antibodies to varicella zoster virus, or both. Exclusion criteria included a history of herpes zoster within the previous year of enrolment, and intended antiviral prophylaxis for longer than 6 months after transplantation. Participants were randomly assigned according to a central randomisation schedule generated by the trial statistician, to receive either the inactivated-virus vaccine from one of three consistency lots, a high-antigen lot, or placebo, stratified by age (< 50 vs >= 50 years) and intended duration of antiviral prophylaxis after transplantation (<= 3 months vs > 3 to <= 6 months). Participants, investigators, trial staff, and the funder's clinical and laboratory personnel were masked to group assignment. Participants were given four doses of inactivated vaccine or placebo, with the first dose 5-60 days before auto-HSCT, and the second, third, and fourth doses at about 30, 60, and 90 days after transplantation. The primary efficacy endpoint was the incidence of herpes zoster, confirmed by PCR or adjudication by a masked clinical committee, or both, assessed in all participants randomly assigned to the vaccine consistency lot group or placebo group who received at least one dose of vaccine and had auto-HSCT. Safety was asses

Published
2018

17. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies.

Author

Zucenka, Andrius, Pileckyte, Regina, Trociukas, Igoris, Peceliunas, Valdas, Vaitekenaite, Vilmante, Maneikis, Kazimieras, Davainis, Linas, Zvirblis, Tadas, Stoskus, Mindaugas, Gineikiene, Egle, Norvilas, Rimvydas, Dirse, Vaidas, Surauciute, Agne, Zucenkiene, Emile, and Griskevicius, Laimonas

Subjects
ACUTE myeloid leukemia, SALVAGE therapy, DACTINOMYCIN, SURVIVAL analysis (Biometry), PALLIATIVE treatment, VENETOCLAX
Abstract

Objectives and methods: We conducted a retrospective analysis to evaluate the outcomes of 28 heavily pretreated (median 3 (2‐6) treatment lines, sixteen (57%) allotransplanted) relapsed/refractory acute myeloid leukemia patients who had failed salvage venetoclax‐based therapies. Results: The median age was 59 years (20‐80), 20 patients (71%) had ECOG 2‐4 status, and 18 patients (64%) were stratified to European Leukemia Network 2017 adverse risk group. The most common mutations were ASXL1 (21%), RUNX1 (18%), FLT3 ITD/TKD (18%), PTPN11 (15%), NRAS/KRAS (15%), and WT1 (15%). Twenty‐two patients (79%) received different post‐venetoclax salvage therapies with the overall response rate of 23% (complete remission + morphological leukemia‐free state). Three of six (50%) patients achieved complete remissions after therapy with venetoclax + actinomycin D ± low‐dose cytarabine. The remaining 6 patients did not receive any further salvage treatment mainly due to poor general condition. The median overall survival was 3.9 months for all patients (4.3 for those receiving post‐venetoclax salvage vs 1.3 months receiving palliative care alone, P <.001). Conclusions: Though the remission rate and survival of patients failing venetoclax are poor, a small proportion of these R/R AML patients may still respond to cautious intensification of chemotherapy with venetoclax. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J, primary, Mullane, Kathleen M, additional, Cornely, Oliver A, additional, Boeckh, Michael J, additional, Brown, Janice Wes, additional, Pergam, Steven A, additional, Trociukas, Igoris, additional, Žák, Pavel, additional, Craig, Michael D, additional, Papanicolaou, Genovefa A, additional, Velez, Juan D, additional, Panse, Jens, additional, Hurtado, Kimberly, additional, Fernsler, Doreen A, additional, Stek, Jon E, additional, Pang, Lei, additional, Su, Shu-Chih, additional, Zhao, Yanli, additional, Chan, Ivan S F, additional, Kaplan, Susan S, additional, Parrino, Janie, additional, Lee, Ingi, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Arvin, Ann, additional, Basso, AC, additional, Bonvehi, P, additional, Cerana, S, additional, Dictar, MO, additional, Campbell, P, additional, Playford, G, additional, Sasadeusz, J, additional, Maertens, J, additional, Poire, X, additional, Sellesag, D, additional, Schots, R, additional, Theunissen, K, additional, Willems, E, additional, Alves, RS, additional, Camargo, JFC, additional, Castro, NS, additional, Maria Fogliatto, L, additional, Rodrigo, O, additional, Courture, F, additional, McGeer, A, additional, Miller, M, additional, Combariza, JF, additional, Sossa, CL, additional, Velez, JD, additional, Nemet, D, additional, Ostojic Kolonic, S, additional, Jebavy, L, additional, Mayer, J, additional, Novak, J, additional, Pohlreich, D, additional, Maldonado, B, additional, Gastinne, T, additional, Karlin, L, additional, Launay, O, additional, Cornely, OA, additional, Duerk, HA, additional, Haenel, M, additional, Heinz, W, additional, Kaufmann, M, additional, Panse, J, additional, Teschner, D, additional, Verbeek, M, additional, Wulf, G, additional, Aviv, F, additional, Grisariu, S, additional, Nagler, A, additional, Yeshurun, M, additional, Bosi, A, additional, Corradini, P, additional, Martinelli, G, additional, Onida, F, additional, Rambaldi, A, additional, Velardi, A, additional, Trociukas, I, additional, Gomez, AD, additional, Wondergem, MJ, additional, Ypma, PF, additional, Fanilla, E, additional, Moreno Larrea, MDC, additional, Abecasis, MM, additional, Ferreira, RB, additional, Geraldes, C, additional, Castro, J, additional, Afanasyev, BV, additional, Kruchkova, IV, additional, Zaritskiy, AY, additional, Cheong, JW, additional, Kim, SJ, additional, Lee, DG, additional, Yoon, SS, additional, Aguado Bueno, B, additional, Jarque Ramos, I, additional, Solano Vercet, C, additional, Cherif, H, additional, Ljungman, P, additional, Vaht, K, additional, Cook, G, additional, Kanfer, E, additional, Milligan, DW, additional, Parker, A, additional, Akard, L, additional, Bachier, C, additional, Ball, ED, additional, Betts, FR, additional, Braunschweig, I, additional, Brown, JM, additional, Carroll, MP, additional, Chandrasekar, PH, additional, Collins, R, additional, Cooper, B, additional, Craig, M, additional, D'Cunha, N, additional, Donato, ML, additional, Essell, J, additional, Flomenberg, P, additional, Freifeld, A, additional, Freytes, C, additional, Guarino, MJ, additional, Hall, MC, additional, Heimenz, JW, additional, High, KP, additional, Isola, LM, additional, Kaminer, L, additional, Klein, LM, additional, Janakiraman, N, additional, Kane, K, additional, Komanduri, K, additional, Krijanovski, OI, additional, Lawrence, SJ, additional, Leis, JF, additional, Lill, M, additional, Longo, WL, additional, Lynch, JP, additional, Mattar, BI, additional, Mehta, J, additional, Mullane, KM, additional, Nathan, S, additional, Papanicolaou, GA, additional, Pergam, SA, additional, Roy, V, additional, Rybka, W, additional, Safah, H, additional, Saltzman, D, additional, Segal, GM, additional, Selby, GB, additional, Schuster, MW, additional, Shoham, S, additional, Sloan, JM, additional, Strasfeld, LM, additional, Styler, M, additional, Sullivan, K, additional, Tse, W, additional, Vance, EA, additional, Winston, DJ, additional, and Yanovich, S, additional

Published
2018
Full Text
View/download PDF

19. Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation

Author

Priluckienė, Janina, Kriukelytė, Indrė, Jurgutis, Mindaugas, and Trociukas, Igoris

Subjects
Nefrozinis sindromas, Nephrotic syndrome, Stem cells--Transplantation, Kamieninės ląstelės--Transplantacija
Abstract

Alogeninių kraujo kamieninių ląstelių persodinimo komplikacijos pagal jų radimosi laiką skirstomos į ankstyvąsias (jei randasi per 100 dienų po persodinimo) ir vėlyvąsias (jei randasi daugiau kaip per 100 dienų po persodinimo). Vėlyvoji komplikacija dažniausiai yra lėtinė liga „transplantatas prieš šeimininką“, kuria suserga 60–80 proc. recipientų. Gerai žinoma, jog liga pažeidžia odos audinius, gleivines, virškinamojo kanalo ar kepenų ląsteles. Inkstai nėra organas-taikinys sergant lėtine liga „transplantatas prieš šeimininką“. Tačiau literatūroje aprašyta atvejų, kai pacientams po alogeninių persodinimo operacijų, inkstų pažeidimas pasireiškė nefroziniu sindromu. Straipsnyje aprašomas lėtinės mieloleukemijos atvejis, kai, atlikus kraujo kamieninių ląstelių persodinimą, pasireiškė nefrozinis sindromas. Atlikus inkstų biopsiją, nustatyta membraninė nefropatija. Gydymas ciklosporinu ir metilprednizolonu žymiai sumažino albu¬minuriją. Complications of allogenic hematopoietic stem cell transplantation that occur in the first 100 days are considered early and those that begin 100 days after are considered late complications. Chronic graft-versus-host disease is the most common late complication of allogenic hematopoietic cell transplantation, which occurs in 60–80% of long-term survivors and causes significant morbidity and mortality. It is well known that it affects primarily the skin, mucous membranes, cells in the gastrointestinal tract and liver. The kidneys are not considered a target organ for chronic graft-versus-host disease in humans, although renal involvement in patients with chronic graft-versus-host disease, presenting as nephrotic syndrome, has been reported in patients who underwent allogenic transplantation. We present a case of chronic graft-versus-host disease that manifested as nephrotic syndrome after hematopoietic cell transplantation performed 3 years ago. Kidney biopsy revealed membrane nephropathy. Treatment with cyclosporine and methylprednisolone significantly reduced albuminuria.

Published
2007

20. [Chronic graft-versus-host disease presenting as nephrotic syndrome after allogenic hematopoietic stem cell transplantation].

Author

Priluckiene J, Kriukelyte I, Jurgutis M, and Trociukas I

Subjects
Adult, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents therapeutic use, Chronic Disease, Cyclosporine administration & dosage, Cyclosporine therapeutic use, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents therapeutic use, Male, Methylprednisolone administration & dosage, Methylprednisolone therapeutic use, Time Factors, Transplantation, Homologous, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation, Nephrotic Syndrome diagnosis
Abstract

Complications of allogenic hematopoietic stem cell transplantation that occur in the first 100 days are considered early and those that begin 100 days after are considered late complications. Chronic graft-versus-host disease is the most common late complication of allogenic hematopoietic cell transplantation, which occurs in 60-80% of long-term survivors and causes significant morbidity and mortality. It is well known that it affects primarily the skin, mucous membranes, cells in the gastrointestinal tract and liver. The kidneys are not considered a target organ for chronic graft-versus-host disease in humans, although renal involvement in patients with chronic graft-versus-host disease, presenting as nephrotic syndrome, has been reported in patients who underwent allogenic transplantation. We present a case of chronic graft-versus-host disease that manifested as nephrotic syndrome after hematopoietic cell transplantation performed 3 years ago. Kidney biopsy revealed membrane nephropathy. Treatment with cyclosporine and methylprednisolone significantly reduced albuminuria.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results